Pneumonitis

Last updated
Pneumonitis
Other namesPulmonitis
Pneumonitis.png
Pneumonitis
Specialty Pulmonology   OOjs UI icon edit-ltr-progressive.svg
CausesFungi ,Virus, Bacteria, Parasite

Pneumonitis describes general inflammation of lung tissue. [1] [2] Possible causative agents include radiation therapy of the chest, [3] exposure to medications used during chemo-therapy, the inhalation of debris (e.g., animal dander), aspiration, herbicides or fluorocarbons and some systemic diseases. If unresolved, continued inflammation can result in irreparable damage such as pulmonary fibrosis. [4]

Contents

Pneumonitis is distinguished from pneumonia on the basis of causation as well as its manifestation. Pneumonia can be described as pneumonitis combined with consolidation and exudation of lung tissue due to infection with microorganisms. [5] The distinction between pneumonia and pneumonitis can be further understood with pneumonitis being the encapsulation of all respiratory infections (incorporating pneumonia and pulmonary fibrosis as major diseases), and pneumonia as a localized infection. [6] For most infections, the immune response of the body is enough to control and apprehend the infection within a couple days, but if the tissue and the cells can't fight off the infection, the creation of pus will begin to form in the lungs which then hardens into lung abscess or suppurative pneumonitis. [6] Patients that are immunodeficient and don't get treated immediately for any type of respiratory infection may lead to more severe infections and/or death. [6]

Pneumonitis can be classified into several different specific subcategories, including hypersensitivity pneumonitis, radiation pneumonitis, acute interstitial pneumonitis, and chemical pneumonitis. These all share similar symptoms, but differ in causative agents. Diagnosis of pneumonitis remains challenging, [7] but several different treatment paths (corticosteroids, oxygen therapy, avoidance) have seen success. [8]

Causes

Alveoli are the primary structure affected by pneumonitis. Any particles that are smaller than 5 microns can enter the alveoli of the lungs. [9] These tiny air sacs facilitate the passage of oxygen from inhaled air to the bloodstream.[ citation needed ] In the case of pneumonitis, it is more difficult for this exchange of oxygen to occur since irritants have caused inflammation of the alveoli. [3] Due to the lack of a definitive determination of a single irritant causing pneumonitis, there are several possible causes. [3]

Symptoms

Physical manifestations of Pneumonitis range from mild cold-like symptoms to respiratory failure. Most frequently, those with pneumonitis experience shortness of breath, and sometimes a dry cough. [8] Symptoms usually appear a few hours after exposure and peak at approximately eighteen to twenty-four hours. [7]

Other symptoms may include:

Without proper treatment, pneumonitis may become chronic pneumonitis, resulting in fibrosis of the lungs and its effects:

End-stage fibrosis and respiratory failure eventually lead to death in cases without proper management of chronic pneumonitis. [7]

Diagnosis

A chest X-ray or CT is necessary to differentiate between pneumonitis and pneumonia of an infectious etiology. Some degree of pulmonary fibrosis may be evident in a CT which is indicative of chronic pulmonary inflammatory processes. Diagnosis of Pneumonitis is often difficult as it depends on a high degree of clinical suspicion when evaluating a patient with a recent onset of a possible interstitial lung disease. In addition, interpreting pathologic and radiographic test results remains a challenge to clinicians. Pneumonitis is often difficult to recognize and discern from other interstitial lung diseases. [7]

Diagnostic procedures currently available include:

Exposure to causative agents of pneumonitis in a specific environment can be confirmed through aero/microbiologic analysis to verify its presence. Subsequent testing of patient serum for evidence of serum specific IgG antibodies confirms patient exposure. [7]

Clinical tests include chest radiography or (HRCT) which may show centrilobular nodular and ground-glass opacities with air-trapping in the middle and upper lobes of the lungs. Fibrosis may also be evident. Bronchoalveolar Lavage (BAL) findings coinciding with pneumonitis typically include a lymphocytosis with a low CD4:CD8 ratio. [7] [13]

Reticular or linear patterns may be observed in diagnostic imaging. [7] Pneumonitis may cause subpleural honeycombing, changing the shape of the air spaces in an image, which may be used to identify the respiratory disease. [7] The interlobular septa may also thicken and indicate pneumonitis when viewed on a scan. [7]

Histological samples of lung tissue with pneumonitis include the presence of poorly formed granulomas or mononuclear cell infiltrates. The presence of bronchocentric lymphohistiocytic interstitial pneumonia with chronic bronchiolitis and non-necrotising granulomas coincides with pneumonitis. [13]

Since pneumonitis manifests in all areas of the lungs, imaging such as chest x-rays and Computerized tomography (CT) scans are useful diagnostic tools. [3] While pneumonia is a localized infection, pneumonitis is widespread. [3] A spirometer may also be used to measure pulmonary function.

During external examination, clubbing (swelling of fingertip tissue and increase in angle at the nail bed), [14] and basal crackles may be observed.

For hypersensitivity pneumonitis many diagnoses take place through the focus of blood test, chest x-rays, and depending on severity of infection doctors may recommend a bronchoscopy. Blood test are important to early detect for other causative substances that could eliminate possible causes of the hypersensitivity pneumonitis. [15]

Classification

Pneumonitis can be separated into several distinct categories based upon causative agent.

Treatment

Typical treatment for pneumonitis includes conservative use of corticosteroids such as a short course of oral prednisone or methylprednisolone. Inhaled corticosteroids such as fluticasone or budesonide may also be effective for reducing inflammation and preventing re-inflammation on a chronic level by suppressing inflammatory processes that may be triggered by environmental exposures such as allergens. Severe cases of pneumonitis may require corticosteroids and oxygen therapy, as well as elimination of exposure to known irritants. [8]

Corticosteroid dose and treatment duration vary from case to case. However, a common regimen beginning at 0.5 mg/kg per day for a couple of days before tapering to a smaller dose for several months to a year, has been used successfully. [13]

Corticosteroids effectively reduce inflammation by switching off several genes activated during an inflammatory reaction. [18] The production of anti-inflammatory proteins, and the degeneration of mRNA encoding inflammatory proteins, can also be increased by a high concentration of corticosteroids. [18] These responses can help mitigate the inflammation seen in pneumonitis and reduce symptoms. [13]

Certain immune-modulating treatments may be appropriate for patients with chronic pneumonitis. Azathioprine and mycophenolate are two particular treatments that have been associated with an improvement of gas exchange. Patients with chronic pneumonitis also may be evaluated for lung transplantation. [13]

Images

See also

Related Research Articles

<span class="mw-page-title-main">Sputum</span> Mucus that is coughed up from the lower airways

Sputum is mucus that is coughed up from the lower airways. In medicine, sputum samples are usually used for a naked eye examination, microbiological investigation of respiratory infections and cytological investigations of respiratory systems. It is crucial that the specimen does not include any mucoid material from the nose or oral cavity.

<span class="mw-page-title-main">Bronchiectasis</span> Disease of the lungs

Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung. Symptoms typically include a chronic cough with mucus production. Other symptoms include shortness of breath, coughing up blood, and chest pain. Wheezing and nail clubbing may also occur. Those with the disease often get lung infections.

<span class="mw-page-title-main">Interstitial lung disease</span> Group of diseases

Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium and space around the alveoli of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.

<span class="mw-page-title-main">Pulmonary fibrosis</span> Disease that causes scarring of the lungs

Pulmonary fibrosis is a condition in which the lungs become scarred over time. Symptoms include shortness of breath, a dry cough, feeling tired, weight loss, and nail clubbing. Complications may include pulmonary hypertension, respiratory failure, pneumothorax, and lung cancer.

Chemical pneumonitis is inflammation of the lung caused by aspirating or inhaling irritants. It is sometimes called a "chemical pneumonia", though it is not infectious. There are two general types of chemical pneumonitis: acute and chronic.

<span class="mw-page-title-main">Hypersensitivity pneumonitis</span> Medical condition

Hypersensitivity pneumonitis (HP) or extrinsic allergic alveolitis (EAA) is a syndrome caused by the repetitive inhalation of antigens from the environment in susceptible or sensitized people. Common antigens include molds, bacteria, bird droppings, bird feathers, agricultural dusts, bioaerosols and chemicals from paints or plastics. People affected by this type of lung inflammation (pneumonitis) are commonly exposed to the antigens by their occupations, hobbies, the environment and animals. The inhaled antigens produce a hypersensitivity immune reaction causing inflammation of the airspaces (alveoli) and small airways (bronchioles) within the lung. Hypersensitivity pneumonitis may eventually lead to interstitial lung disease.

Eosinophilic pneumonia is a disease in which an eosinophil, a type of white blood cell, accumulates in the lungs. These cells cause disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere. Several different kinds of eosinophilic pneumonia exist and can occur in any age group. The most common symptoms include cough, fever, difficulty breathing, and sweating at night. Eosinophilic pneumonia is diagnosed by a combination of characteristic symptoms, findings on a physical examination by a health provider, and the results of blood tests and X-rays. Prognosis is excellent once most eosinophilic pneumonia is recognized and treatment with corticosteroids is begun.

<span class="mw-page-title-main">Cryptogenic organizing pneumonia</span> Medical condition

Cryptogenic organizing pneumonia (COP), formerly known as bronchiolitis obliterans organizing pneumonia (BOOP), is an inflammation of the bronchioles (bronchiolitis) and surrounding tissue in the lungs. It is a form of idiopathic interstitial pneumonia.

<span class="mw-page-title-main">Respiratory disease</span> Disease of the respiratory system

Respiratory diseases, or lung diseases, are pathological conditions affecting the organs and tissues that make gas exchange difficult in air-breathing animals. They include conditions of the respiratory tract including the trachea, bronchi, bronchioles, alveoli, pleurae, pleural cavity, the nerves and muscles of respiration. Respiratory diseases range from mild and self-limiting, such as the common cold, influenza, and pharyngitis to life-threatening diseases such as bacterial pneumonia, pulmonary embolism, tuberculosis, acute asthma, lung cancer, and severe acute respiratory syndromes, such as COVID-19. Respiratory diseases can be classified in many different ways, including by the organ or tissue involved, by the type and pattern of associated signs and symptoms, or by the cause of the disease.

<span class="mw-page-title-main">Farmer's lung</span> Hypersensitivity pneumonitis

Farmer's lung is a hypersensitivity pneumonitis induced by the inhalation of biologic dusts coming from hay dust or mold spores or any other agricultural products. It results in a type III hypersensitivity inflammatory response and can progress to become a chronic condition which is considered potentially dangerous.

Occupational lung diseases comprise a broad group of diseases, including occupational asthma, industrial bronchitis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, inhalation injury, interstitial lung diseases, infections, lung cancer and mesothelioma. These can be caused directly or due to immunological response to an exposure to a variety of dusts, chemicals, proteins or organisms. Occupational cases of interstitial lung disease may be misdiagnosed as COPD, idiopathic pulmonary fibrosis, or a myriad of other diseases; leading to a delay in identification of the causative agent.

<span class="mw-page-title-main">Idiopathic pulmonary fibrosis</span> Medical condition

Idiopathic pulmonary fibrosis (IPF), or (formerly) fibrosing alveolitis, is a rare, progressive illness of the respiratory system, characterized by the thickening and stiffening of lung tissue, associated with the formation of scar tissue. It is a type of chronic scarring lung disease characterized by a progressive and irreversible decline in lung function. The tissue in the lungs becomes thick and stiff, which affects the tissue that surrounds the air sacs in the lungs. Symptoms typically include gradual onset of shortness of breath and a dry cough. Other changes may include feeling tired, and abnormally large and dome shaped finger and toenails. Complications may include pulmonary hypertension, heart failure, pneumonia or pulmonary embolism.

<span class="mw-page-title-main">Bird fancier's lung</span> Type of hypersensitivity pneumonitis

Bird fancier's lung (BFL), also known as bird breeder's lung, is a type of hypersensitivity pneumonitis. It can cause shortness of breath, fever, dry cough, chest pain, anorexia and weight loss, fatigue, and progressive pulmonary fibrosis. It is triggered by exposure to avian proteins present in the dry dust of droppings or feathers of a variety of birds. The lungs become inflamed, with granuloma formation. It mostly affects people who work with birds or own many birds.

<span class="mw-page-title-main">Usual interstitial pneumonia</span> Medical condition

Usual interstitial pneumonia (UIP) is a form of lung disease characterized by progressive scarring of both lungs. The scarring (fibrosis) involves the pulmonary interstitium. UIP is thus classified as a form of interstitial lung disease.

Restrictive lung diseases are a category of extrapulmonary, pleural, or parenchymal respiratory diseases that restrict lung expansion, resulting in a decreased lung volume, an increased work of breathing, and inadequate ventilation and/or oxygenation. Pulmonary function test demonstrates a decrease in the forced vital capacity.

Pulmonary toxicity is the medical name for side effects on the lungs.

<span class="mw-page-title-main">Acute exacerbation of chronic obstructive pulmonary disease</span> Medical condition

An acute exacerbation of chronic obstructive pulmonary disease, or acute exacerbations of chronic bronchitis (AECB), is a sudden worsening of chronic obstructive pulmonary disease (COPD) symptoms including shortness of breath, quantity and color of phlegm that typically lasts for several days.

<span class="mw-page-title-main">Lycoperdonosis</span> Medical condition

Lycoperdonosis is a respiratory disease caused by the inhalation of large amounts of spores from mature puffballs. It is classified as a hypersensitivity pneumonitis —an inflammation of the alveoli within the lung caused by hypersensitivity to inhaled natural dusts. It is one of several types of hypersensitivity pneumonitis caused by different agents that have similar clinical features. Typical progression of the disease includes symptoms of a cold hours after spore inhalation, followed by nausea, rapid pulse, crepitant rales, and dyspnea. Chest radiographs reveal the presence of lung nodules. The early symptoms presented in combination with pulmonary abnormalities apparent on chest radiographs may lead to misdiagnosis of the disease as tuberculosis, histiocytosis, or pneumonia caused by Pneumocystis carinii. Lycoperdonosis is generally treated with corticosteroids, which decrease the inflammatory response; these are sometimes given in conjunction with antimicrobials.

<span class="mw-page-title-main">Ground-glass opacity</span> Radiologic sign on radiographs and computed tomography scans

Ground-glass opacity (GGO) is a finding seen on chest x-ray (radiograph) or computed tomography (CT) imaging of the lungs. It is typically defined as an area of hazy opacification (x-ray) or increased attenuation (CT) due to air displacement by fluid, airway collapse, fibrosis, or a neoplastic process. When a substance other than air fills an area of the lung it increases that area's density. On both x-ray and CT, this appears more grey or hazy as opposed to the normally dark-appearing lungs. Although it can sometimes be seen in normal lungs, common pathologic causes include infections, interstitial lung disease, and pulmonary edema.

<span class="mw-page-title-main">Emphysema</span> Medical condition

Emphysema is any air-filled enlargement in the body's tissues. Most commonly emphysema refers to the enlargement of air spaces (alveoli) in the lungs, and is also known as pulmonary emphysema.

References

  1. "pneumonitis" at Dorland's Medical Dictionary
  2. Stedman's medical dictionary (28th ed.). Philadelphia: Lippincott Williams & Wilkins. 2006. ISBN   978-0-7817-6450-6.
  3. 1 2 3 4 5 6 7 8 9 10 11 "Pneumonitis - Symptoms and causes". mayoclinic.com.
  4. 1 2 "Pneumonitis. Medical information about Pneumonitis". www.patient.co.uk. 28 July 2020. Archived from the original on 15 March 2012. Retrieved 31 January 2008.
  5. "pneumonia" at Dorland's Medical Dictionary
  6. 1 2 3 4 5 6 Maxwell J (July 1938). "Pneumonitis". The Lancet. 232 (5996): 239–41. doi:10.1016/S0140-6736(00)98250-3.
  7. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Miller R, Allen TC, Barrios RJ, Beasley MB, Burke L, Cagle PT, et al. (January 2018). "Hypersensitivity Pneumonitis A Perspective From Members of the Pulmonary Pathology Society". Archives of Pathology & Laboratory Medicine. 142 (1): 120–126. doi: 10.5858/arpa.2017-0138-SA . PMID   28613913.
  8. 1 2 3 4 "Pneumonitis - Diagnosis and treatment - Mayo Clinic". www.mayoclinic.org. Retrieved 2020-03-26.
  9. "Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis) : OSH Answers". Canadian Centre for Occupational Health and Safety. Government of Canada. 2020-03-26. Retrieved 2020-03-26.
  10. Sierra-Rodero, B; Cruz-Bermúdez, A; Nadal, E; Garitaonaindía, Y; Insa, A; Mosquera, J; Casal-Rubio, J; Dómine, M; Majem, M; Rodriguez-Abreu, D; Martinez-Marti, A; De Castro Carpeño, J; Cobo, M; López Vivanco, G; Del Barco, E; Bernabé Caro, R; Viñolas, N; Barneto Aranda, I; Viteri, S; Massuti, B; Laza-Briviesca, R; Casarrubios, M; García-Grande, A; Romero, A; Franco, F; Provencio, M (August 2021). "Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial". Journal for Immunotherapy of Cancer. 9 (8): e002804. doi:10.1136/jitc-2021-002804. PMC   8395363 . PMID   34446577.
  11. https://www.cdc.gov/niosh/docs/81-123/pdfs/0565.pdf [ bare URL PDF ]
  12. "Mushroom Toxicity: Background, Pathophysiology, Etiology". 6 January 2017 via eMedicine.{{cite journal}}: Cite journal requires |journal= (help)
  13. 1 2 3 4 5 Vasakova M, Morell F, Walsh S, Leslie K, Raghu G (September 2017). "Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management". American Journal of Respiratory and Critical Care Medicine. 196 (6): 680–689. doi:10.1164/rccm.201611-2201PP. PMID   28598197. S2CID   40479842.
  14. 1 2 "Evaluation of the Pulmonary Patient - Pulmonary Disorders". Merck Manuals Professional Edition. Retrieved 2020-03-26.
  15. "Hypersensitivity Pneumonitis - Pulmonary Disorders". Merck Manuals Professional Edition. Retrieved 2020-03-26.
  16. 1 2 Keffer S, Guy CL, Weiss E (2020). "Fatal Radiation Pneumonitis: Literature Review and Case Series". Advances in Radiation Oncology. 5 (2): 238–249. doi:10.1016/j.adro.2019.08.010. PMC   7136627 . PMID   32280824.
  17. 1 2 3 4 Marik PE (March 2001). "Aspiration pneumonitis and aspiration pneumonia". The New England Journal of Medicine. 344 (9): 665–71. doi:10.1056/NEJM200103013440908. PMID   11228282.
  18. 1 2 Barnes PJ (June 2006). "How corticosteroids control inflammation: Quintiles Prize Lecture 2005". British Journal of Pharmacology. 148 (3): 245–54. doi:10.1038/sj.bjp.0706736. PMC   1751559 . PMID   16604091.